Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...
Genmab (GMAB) Gets a Hold from Morgan Stanley
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...
Leerink Partnrs Estimates Genmab A/S Q3 Earnings
Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the ...
Investing.com on MSN5d
Genmab stock surges on strong profit beat
Investing.com -- Shares of Genmab (NASDAQ:GMAB) climbed 7% following the announcement of its fourth-quarter earnings, which revealed a net profit significantly surpassing consensus estimates. The ...
Blue Trust Inc. Grows Stock Position in Genmab A/S (NASDAQ:GMAB)
Blue Trust Inc. grew its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 33.4% during the fourth quarter, ...
Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...
Genmab upgraded to Outperform from Market Perform at Leerink
Leerink analyst Jonathan Chang upgraded Genmab (GMAB) to Outperform from Market Perform with a $27 price target, citing a longer-term view ...
Genmab stock rating raised, price target cut by BNP Paribas Exane
Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target ...
Why Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to Analysts
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...